CASTLE BIOSCIENCES, INC. financials

CSTL CIK 0001447362

Source: EDGAR filings · Built 2026-06-02T02:45:08Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 28.21M 36.44M -19.39M -47.41M -22.47M 5.11M
EBITDA -2.04M 24.67M -55.65M -62.31M -36.67M -6.07M
Working Capital 292.42M 310.76M 247.97M 256.16M 328.86M 408.72M
Net Debt -79.71M -93.26M -83.44M -109.40M -321.32M -409.85M
Gross Margin 79.37% 81.87% 79.53% 76.64% 83.18% 84.54%
Operating Margin -12.44% 2.61% -30.93% -53.16% -42.60% -10.44%
Net Margin -7.02% 5.49% -26.15% -48.99% -33.26% -16.42%
Return on Equity (ROE) -5.13% 4.00% -14.69% -16.82% -7.60% -2.47%
Return on Assets (ROA) -4.18% 3.43% -12.68% -15.01% -6.76% -2.34%
Current Ratio 5.26× 7.29× 6.20× 8.09× 14.21× 20.58×
Debt-to-Equity 0.08× 0.06× 0.04× 0.03× 0.02× 0.00×
Cash Conversion Ratio -2.66× 3.56× 0.10× 0.62× 0.61× -0.96×
Accruals Ratio -0.15× -0.09× -0.11× -0.06× -0.03× -0.05×
SBC % of Revenue 13.33% 15.15% 23.30% 26.50% 23.11% 13.26%
CapEx Coverage 1.78× 2.28× -0.41× -7.24× -5.44× 2.08×
Free Cash Flow Per Share $0.97 $1.25 $-0.72 $-1.82 $-0.89 $0.27

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 42.98×
P/FCF 39.97× 21.39× 248.52×
FCF Yield 2.50% 4.67% 0.40%
EV / EBITDA 26.99×
P/S 3.35× 2.29× 2.69× 4.56× 11.56× 26.60×
P/B 2.45× 1.67× 1.51× 1.57× 2.64× 4.01×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 344.23M 332.07M 219.79M 137.04M 94.08M 62.65M
Cost of Goods and Services Sold 15.82M 9.69M
Cost of Revenue 71.03M 60.20M 44.98M 32.01M 15.82M
Gross Profit 52.96M
Research and Development Expense 51.85M 52.04M 53.62M 44.90M 29.65M 13.26M
Selling, General and Administrative Expense 229.32M 200.05M 180.15M 143.00M 86.74M 48.13M
Operating Income (Loss) -42.81M 8.67M -67.98M -72.86M -40.08M -6.54M
Income Tax Expense (Benefit) -5.36M 3.32M 101.00K -1.77M -8.72M 84.00K
Net Income (Loss) Attributable to Parent -24.16M 18.25M -57.47M -67.14M -31.29M -10.28M
Earnings Per Share, Basic $-0.83 $0.66 $-2.14 $-2.58 $-1.24 $-0.54
Weighted Average Number of Shares Outstanding, Basic 28.99M 27.78M 26.80M 26.05M 25.14M 18.93M
Earnings Per Share, Diluted $-0.83 $0.62 $-2.14 $-2.58 $-1.24 $-0.54
Weighted Average Number of Shares Outstanding, Diluted 28.99M 29.25M 26.80M 26.05M 25.14M 18.93M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 116.73M 119.71M 98.84M 122.95M 329.63M 409.85M
Assets, Current 361.10M 360.15M 295.63M 292.29M 353.74M 429.59M
Assets 578.56M 531.24M 453.34M 447.33M 462.57M 439.33M
Long-term Debt 10.06M 10.02M 0
Liabilities, Current 68.68M 49.39M 47.67M 36.13M 24.89M 20.88M
Long-term Debt, Excluding Current Maturities 9.64M 9.74M 0 0
Liabilities 107.68M 75.40M 62.07M 48.18M 50.83M 23.64M
Stockholders' Equity Attributable to Parent 470.87M 455.83M 391.27M 399.15M 411.74M 415.69M
Common Stock, Shares, Outstanding 29.69M 28.48M 27.41M 26.55M 25.38M 24.81M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 64.35M 64.87M -5.63M -41.66M -18.98M 9.87M
Payments to Acquire Property, Plant, and Equipment 36.02M 28.33M 13.62M 5.63M 3.48M 4.75M
Net Cash Provided by (Used in) Investing Activities -60.37M -50.14M -16.18M -166.54M -66.66M -4.75M
Net Cash Provided by (Used in) Financing Activities -6.96M 6.14M -2.30M 1.51M 5.42M 305.89M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CSTL CIK 0001447362), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

COCO

The Vita Coco Company, Inc.

LXEO

Lexeo Therapeutics, Inc.

THFF

FIRST FINANCIAL CORPORATION